CytoReason Revenue and Competitors
Estimated Revenue & Valuation
- CytoReason's estimated annual revenue is currently $33.8M per year.
- CytoReason's estimated revenue per employee is $201,000
Employee Data
- CytoReason has 168 Employees.
- CytoReason grew their employee count by 24% last year.
CytoReason's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP R&D | Reveal Email/Phone |
2 | Project Manager | Reveal Email/Phone |
3 | Strategic Consultant | Reveal Email/Phone |
CytoReason Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $16.7M | 83 | -34% | $237M | N/A |
#2 | $7.8M | 39 | -2% | N/A | N/A |
#3 | $33.8M | 168 | 24% | N/A | N/A |
#4 | $11.3M | 56 | 19% | N/A | N/A |
#5 | $10.3M | 51 | -12% | N/A | N/A |
#6 | $11.7M | 58 | 1060% | N/A | N/A |
#7 | $9.6M | 48 | 41% | N/A | N/A |
What Is CytoReason?
CytoReason turns human clinical data into clear biology, to deliver data-driven target discovery and drug development. CytoReason?s access to unmatched proprietary and public data, combined with cutting-edge machine learning technologies, creates our unique biological models of disease, tissue and drug. Using our molecular-level disease models we turn human clinical data into biology, mapping what the cells, genes and proteins are doing in a disease, tissue and treatment environment. This enables us to uncover disease and drug mechanisms of action and turn that biology into clinical edge, by delivering valuable IP in the form of novel targets, indications, combinations and biomarkers.
keywords:N/A
N/A
Total Funding
168
Number of Employees
$33.8M
Revenue (est)
24%
Employee Growth %
N/A
Valuation
N/A
Accelerator
CytoReason News
The partnership will see Helixrus represent CytoReason's AI platform and professional services in the Korean market.
Israel's CytoReason, a leading developer of computational disease models for efficient drug discovery and development, has announced the...
CytoReason, a developer of computational disease models for efficient drug discovery and development, has signed a commercial partnership...
TEL AVIV, Israel, May 19, 2021 /PRNewswire/ -- CytoReason, an Israeli company developing a computational model of the human body for faster drug discovery and development, today announced a collaboration with Swiss multinational biopharmaceutical company, Ferring Pharmaceuticals, which aims to ...
TEL AVIV, Israel–(BUSINESS WIRE)–January 7, 2019– CytoReason, a leader in machine learning for drug discovery and development, announced today that it has entered into a collaboration agreement with Pfizer Inc. (NYSE:PFE) that will leverage CytoReason’s cell-centered models of the immune system ...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $53.6M | 168 | 4% | N/A |
#2 | $15M | 168 | 6% | N/A |
#3 | $60.6M | 168 | 6% | N/A |
#4 | $45.3M | 168 | 6% | N/A |
#5 | $18.5M | 168 | N/A | N/A |